XVIVO — Xvivo Perfusion AB Share News
0.000.00%
- SEK6.49bn
- SEK6.30bn
- SEK812.17m
Brief: Xvivo: Results From Clinical Trial NIHP2019 For Heart Preservation
Brief: Xvivo Q4 EBIT SEK -16.1 Million
Brief: Xvivo Says Extended Perfusion Time Of Livers Can Streamline Planning, Logistics
Brief: Xvivo Q3 EBIT SEK 5.3 Million
Brief: Xvivo Carries Out Directed Share Issue Of 1.6 Mln Shares
Brief: Xvivo Gets FDA Approval To Include DCD Hearts In IDE Clinical Study
Brief: Xvivo Q2 EBIT SEK 3.8 Million
Brief: Xvivo Enters Into Strategic Collaboration With MTJ Aviation
Brief: Xvivo's IDE Application For Heart Preservation Technology Approved By FDA
Brief: Xvivo Posts Q1 Net Income of SEK 14.2 Million
Brief: Xvivo Perfusion Q4 Adjusted EBITDA Rises To SEK 19.8 Mln
Christoffer Rosenblad Appointed as CEO of XVIVO
Brief: Xvivo Perfusion Q3 EBITDA Grows To SEK 5.9 Mln
Brief: Xvivo Perfusion's CEO Dag Andersson Passes Away
Brief: Xvivo's Strategy For Period 2023-27 Has Been Updated
Brief: Xvivo Liver Assist Device Receives Breakthrough Device Designation From FDA
Brief: Xvivo Enters Into Agreement To Acquire Its Italian Distributor
Brief: Xvivo Perfusion Q2 Adjusted EBITDA Rises To SEK 11.3 Mln
Brief: Xvivo Perfusion In Partnership With Cleveland Clinic